Clinical characteristics of the neonates included in the study
| Non-cooled (n=16) | Cooled (n=15) | p Value | |
|---|---|---|---|
| Gestational age (weeks) | 41 (40-41) | 40 (40-41) | 0.300 |
| Birth weight (g) | 3488 (3163−3733) | 3275 (3000−4130) | 0.707 |
| Gender (male:female) | 10:6 | 9:6 | 0.886* |
| Clinical Sarnat score | |||
| Moderate | 6 | 8 | 0.376* |
| Severe | 10 | 7 | |
| 5-min Apgar score | 6 (2–8) | 4 (2–4) | 0.050 |
| First pH | 7.134 (7.032−7.217) | 6.930 (6.800−7.100) | 0.009 |
| Number of anticonvulsants | 2 (1–3) | 1 (1-2) | 0.274 |
| First-line anticonvulsant (age in h) | 12 (9–19) | 14 (10–24) | 0.504 |
| Total dose of first-line anticonvulsant (mg/kg) | 30 (20–40) | 20 (20) | 0.203 |
| Second-line anticonvulsant (age in h) | 28 (24–31) | 26 (19–38) | 0.556 |
| Number of neonates on morphine | 8 | 15 | 0.002* |
Data are median (IQR) or n.
↵* χ2 test for the proportion of gender and clinical Sarnat score for neonatal hypoxia-ischaemic encephalopathy in non-cooled and cooled groups.